Active	Status	Sponsor type	Region	Phase	Filter
4 Active 21 Inactive 25 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hernandez, Michelle
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®	Active, not recruiting	N/A	718	Europe, Canada, Japan, US	DUPIXENT®, dupilumab, REGN668, SAR231893	Regeneron Pharmaceuticals, Sanofi	Asthma	07/26	07/26